Evidence map›Paper›PMID 40180950›Full record

ArticleSchizophrenia (Heidelberg, Germany)2025

Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.

Nora Penzel, Pablo Polosecki, Jean Addington, Celso Arango, Ameneh Asgari-Targhi, Tashrif Billah, Sylvain Bouix, Monica E Calkins, Dylan E Campbell, Tyrone D Cannon and 53 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

63 authors.

Nora Penzel *Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1624-386X
Pablo Polosecki *IBM T.J. Watson Research Center, Yorktown Heights, NY, USA.
Jean AddingtonDepartment of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.ORCID http://orcid.org/0000-0002-8298-0756
Celso ArangoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, Instituto de Salud Carlos III, School of Medicine, Universidad Complutense, Madrid, Spain.ORCID http://orcid.org/0000-0003-3382-4754
Ameneh Asgari-TarghiDepartment of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Tashrif BillahDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Sylvain BouixDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1326-6054
Monica E CalkinsDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Dylan E CampbellDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0009-0008-5414-2801
Tyrone D CannonDepartments of Psychology and Psychiatry, Yale University, New Haven, CT, USA.
Eduardo CastroIBM T.J. Watson Research Center, Yorktown Heights, NY, USA.ORCID http://orcid.org/0000-0002-7788-9069
Kang Ik K ChoDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7135-3848
Michael J ColemanDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Cheryl M CorcoranDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-8902-4353
Dominic DwyerCentre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-3949-5867
Sophia FrangouDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-3210-6470
Paolo Fusar-PoliDepartment of Psychosis Studies, King's College, London, UK.
Robert J GlynnDepartment of Biostatistics, Harvard T.H. Chan School of Public Health and Harvard Medical School, Boston, MA, USA.
Anastasia HaidarDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Michael P HarmsDepartment of Psychiatry, Washington University Medical School, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-7945-036X
Grace R JacobsDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9961-6507
Joseph KambeitzDepartment of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-8988-3959
Tina KapurDepartment of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Sinead M KellyDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Nikolaos KoutsoulerisDepartment of Psychosis Studies, King's College, London, UK.ORCID http://orcid.org/0000-0001-6825-6262
K R AbhinandanData and Analytics, Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, USA.
Saryet KucukemirogluCenter for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA.
Jun Soo KwonDepartment of Psychiatry, Seoul National University College of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0002-1060-1462
Kathryn E LewandowskiPsychotic Disorders Division, McLean Hospital, Belmont, MA, USA.ORCID http://orcid.org/0000-0003-1477-6187
Qingqin S LiJRD Data Science, Janssen Research & Development, LLC, Titusville, NJ, USA.
Valentina MantuaDivision of Psychiatry, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Daniel H MathalonDepartment of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Vijay A MittalDepartment of Psychology, Northwestern University, Evanston, IL, USA.ORCID http://orcid.org/0000-0001-9017-5119
Spero NicholasVeterans Affairs San Francisco Health Care System, San Francisco, CA, USA.
Gahan J PandinaJohnson & Johnson Innovative Medicine, Titusville, NJ, USA.
Diana O PerkinsDepartment of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-9396-2206
Andrew PotterFood and Drug Administration, Silver Spring, MD, USA.
Abraham ReichenbergDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jenna ReinenIBM T.J. Watson Research Center, Yorktown Heights, NY, USA.
Michael S SandS2 Consulting LLC, Danbury, CT, USA.
Johanna Seitz-HollandDepartment of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1815-2681
Jai L ShahDouglas Research Centre, Montreal, QC, Canada.
Vairavan SrinivasanJohnson & Johnson Innovative Medicine, Titusville, NJ, USA.
Agrima SrivastavaDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
William S StoneDepartment of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
John TorousDepartment of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5362-7937
Mark G VangelDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Jijun WangShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, 200030, China.ORCID http://orcid.org/0000-0001-5427-7425
Phillip WolffDepartment of Psychology, Emory University, Atlanta, USA.
Beier YaoPsychotic Disorders Division, McLean Hospital, Belmont, MA, USA.
Alan AnticevicDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Daniel H WolfDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-9731-8781
Hao ZhuFood and Drug Administration, Silver Spring, MD, USA.
Carrie E BeardenDepartments of Psychiatry and Biobehavioral Sciences & Psychology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-8516-923X
Patrick D McGorryCentre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia.
Barnaby NelsonCentre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia.
John M KaneDepartment of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Scott W WoodsDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-3103-5228
René S KahnDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5909-8004
Martha E ShentonDepartment of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4235-7879
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ)
Guillermo CecchiIBM T.J. Watson Research Center, Yorktown Heights, NY, USA.ORCID http://orcid.org/0000-0003-1013-8348
Ofer PasternakDepartment of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ofer@bwh.harvard.edu.

Funding

ProNET: Psychosis-Risk Outcomes NetworkU01MH124639 · NIMH · YALE UNIVERSITY · PI CARRIE E BEARDEN, JOHN M KANE · 2020 to 2026
$81.2M
Psychosis Risk Evaluation, Data Integration and Computational Technologies (PREDICT): Data Processing, Analysis, and Coordination CenterU24MH124629 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI Rene S. Kahn, Martha E. Shenton · 2020 to 2026
$32.6M
Trajectories and Predictors in the Clinical High Risk for Psychosis Population: Prediction Scientific Global Consortium (PRESCIENT)U01MH124631 · NIMH · UNIVERSITY OF MELBOURNE · PI Christopher Barnaby Nelson · 2020 to 2026
$30.4M
NIMH NIH HHS U01 MH124631NIMH NIH HHS U01 MH124639NIMH NIH HHS U24 MH124629Wellcome Trust
6 · The paper itself

Abstract

The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project assesses a large sample of individuals at clinical high-risk for developing psychosis (CHR) and community controls. Subjects are enrolled in 43 sites across 5 continents. The assessments include domains similar to those acquired in previous CHR studies along with novel domains that are collected longitudinally across a period of 2 years. In parallel with the data acquisition, multidisciplinary teams of experts have been working to formulate the data analysis strategy for the AMP SCZ project. Here, we describe the key principles for the data analysis. The primary AMP SCZ analysis aim is to use baseline clinical assessments and multimodal biomarkers to predict clinical endpoints of CHR individuals. These endpoints are defined for the AMP SCZ study as transition to psychosis (i.e., conversion), remission from CHR syndrome, and persistent CHR syndrome (non-conversion/non-remission) obtained at one year and two years after baseline assessment. The secondary aim is to use longitudinal clinical assessments and multimodal biomarkers from all time points to identify clinical trajectories that differentiate subgroups of CHR individuals. The design of the analysis plan is informed by reviewing legacy data and the analytic approaches from similar international CHR studies. In addition, we consider properties of the newly acquired data that are distinct from the available legacy data. Legacy data are used to assist analysis pipeline building, perform benchmark experiments, quantify clinical concepts and to make design decisions meant to overcome the challenges encountered in previous studies. We present the analytic design of the AMP SCZ project, mitigation strategies to address challenges related to the analysis plan, provide rationales for key decisions, and present examples of how the legacy data have been used to support design decisions for the analysis of the multimodal and longitudinal data. Watch Prof. Ofer Pasternak discuss his work and this article: https://vimeo.com/1023394132?share=copy#t=0 .

Identifiers

PMID40180950
PMCPMC11968818

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.